Published on 20 Mar 2024 on Zacks via Yahoo Finance
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Crinetics Pharmaceuticals’ CRNX shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly.
Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone.
The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants with acromegaly who are treatment-naïve or not currently receiving medical therapy.